Serum angiogenesis-hypoxia biomarkers in relapsing-remitting multiple sclerosis.
Mult Scler Relat DisordJun 29, 2026 (epub)
Clinical ResearchNeurology
Heather Y F Yong, Nicholas J Batty, Serena Phillips et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated serum angiogenesis and hypoxia biomarkers in 122 participants with relapsing-remitting multiple sclerosis (RRMS) compared to 78 healthy controls. The study found that hypoxic markers were increased in RRMS, while angiogenic markers remained unchanged, suggesting a relatively preserved hypoxia-angiogenic axis in RRMS compared to progressive MS.
Key findings
- Increased levels of hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90 were found in RRMS serum.
- Brain derived neurotrophic factor was reduced in RRMS participants.
- Lysyl oxidase levels correlated negatively with lesion texture and brain volume.
Why it matters
Understanding the differences in biomarker profiles between relapsing-remitting and progressive multiple sclerosis can inform treatment strategies and enhance the understanding of disease mechanisms, potentially guiding future therapeutic developments.